<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2104210691
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Broncast Pediatric Chewable Tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        MONTELUKAST SODIUM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        4
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Chewable tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        60.00
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="(Avalon Pharma) Middle East Pharmaceutical Industries Co. Ltd" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            (Avalon Pharma) Middle East Pharmaceutical Industries Co. Ltd
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 437]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Middle East Pharmaceutical Industries Co Ltd Avalon Pharma
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Middle East Pharmaceutical Industries Co Ltd Avalon Pharma
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        R03DC03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Broncast Paediatric 4mg is<br />Broncast Paediatric is a leukotriene receptor antagonist that blocks substances called leukotrienes.<br />How Broncast Paediatric 4mg works<br />Leukotrienes cause narrowing and swelling of airways in the lungs. By blocking leukotrienes,<br />Broncast Paediatric 4mg improves asthma symptoms and helps control asthma.<br />When Broncast Paediatric 4mg should be used<br />Your doctor has prescribed Broncast Paediatric 4mg to treat your child&rsquo;s asthma, preventing<br />asthma symptoms during the day and night.<br />&bull; Broncast Paediatric 4mg is used for the treatment of 2 to 5 years old patients who are not<br />adequately controlled on their medication and need additional therapy.<br />&bull; Broncast Paediatric 4mg may also be used as an alternative treatment to inhaled corticosteroids<br />for 2 to 5 years old patients who have not recently taken oral corticosteroids for their asthma and<br />have shown that they are unable to use inhaled corticosteroids.<br />&bull; Broncast Paediatric 4mg also helps prevent the narrowing of airways triggered by exercise for<br />patients 2 years of age and older.<br />Your doctor will determine how Broncast Paediatric 4mg should be used depending on the<br />symptoms and severity of your child&#39;s asthma.<br />What is asthma?<br />Asthma is a long-term disease.<br />Asthma includes:<br />&bull; difficulty breathing because of narrowed airways. This narrowing of airways worsens and improves<br />in response to various conditions.<br />&bull; sensitive airways that react to many things, such as cigarette smoke, pollen, cold air, or exercise.<br />&bull; swelling (inflammation) in the lining of the airways.<br />Symptoms of asthma include: Coughing, wheezing, and chest tightness.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>2. What you need to know before your child takes Broncast Paediatric 4mg<br />Tell your doctor about any medical problems or allergies your child has now or has had.<br />Do not give Broncast Paediatric 4mg to your child<br />&bull; if he/she is allergic to montelukast or any of the other ingredients of this medicine (listed in section 6).<br />Warnings and precautions<br />Talk to your doctor or pharmacist before you give Broncast Paediatric 4mg to your child.<br />&bull; If your child&rsquo;s asthma or breathing gets worse, tell your doctor immediately.<br />&bull; Oral Broncast Paediatric 4mg is not meant to treat acute asthma attacks. If an attack occurs,<br />follow the instructions your doctor has given you for your child. Always have your child&rsquo;s inhaled<br />rescue medicine for asthma attacks with you.<br />&bull; It is important that your child take all asthma medications prescribed by your doctor. Broncast<br />Paediatric 4mg should not be used instead of other asthma medications your doctor has prescribed<br />for your child.<br />&bull; If your child is on anti-asthma medicines, be aware that if he/she develops a combination of<br />symptoms such as flu-like illness, pins and needles or numbness of arms or legs, worsening of<br />pulmonary symptoms, and/or rash, you should consult your doctor.<br />&bull; Your child should not take acetyl-salicylic acid (aspirin) or anti-inflammatory medicines (also known<br />as non-steroidal anti-inflammatory drugs or NSAIDs) if they make his/her asthma worse.<br />Patients should be aware that various neuropsychiatric events (for example behaviour and moodrelated<br />changes) have been reported in adults, adolescents and children with Broncast (see section<br />4). If your child develops such symptoms while taking Broncast, you should consult your child&rsquo;s doctor.<br />Children and adolescents<br />Do not give this medicine to children less than 2 years of age.<br />There are different form(s) of this medicine available for paediatric patients under 18 years of age<br />based on age range.<br />Other medicines and Broncast Paediatric 4 mg<br />Tell your doctor or pharmacist if your child is taking or has recently been given or might be given any<br />other medicines including those obtained without a prescription.<br />Some medicines may affect how Broncast Paediatric 4mg works, or Broncast Paediatric 4mg<br />may affect how your child&rsquo;s other medicines work.<br />Tell your doctor if your child is taking the following medicines before starting Broncast Paediatric 4mg:<br />&bull; phenobarbital (used for treatment of epilepsy)<br />&bull; phenytoin (used for treatment of epilepsy)<br />&bull; rifampicin (used to treat tuberculosis and some other infections)<br />Broncast Paediatric 4mg with food and drink<br />Broncast Paediatric 4 mg chewable tablets should not be taken immediately with food; they should<br />be taken at least 1 hour before or 2 hours after food.<br />Pregnancy and breastfeeding<br />This subsection is not applicable for the Broncast Paediatric 4 mg chewable tablets since they are<br />intended for use in children 2 to 5 years of age.<br />Driving and using machines<br />This subsection is not applicable for the Broncast Paediatric 4 mg chewable tablets since they are<br />intended for use in children 2 to 5 years of age, however the following information is relevant to the<br />active ingredient, montelukast.<br />Broncast Paediatric 4mg is not expected to affect your ability to drive a car or operate machinery.<br />However, individual responses to medication may vary. Certain side effects (such as dizziness and<br />drowsiness) that have been reported with Broncast Paediatric 4mg may affect some patients&rsquo;<br />ability to drive or operate machinery.<br />Broncast Paediatric 4 mg chewable tablets contain aspartame, a source of phenylalanine<br />and sodium<br />If your child has phenylketonuria (a rare, hereditary disorder of the metabolism) you should take<br />into account that each 4 mg chewable tablet contains 0.08 mg of aspartame which is equivalent to<br />0.0449 mg of Phenylalanine.<br />This medicine contains less than 1 mmol (23 mg) per tablet, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always have your child take this medicine exactly as your doctor or pharmacist has told you. Check with<br />your child&rsquo;s doctor or pharmacist if you are not sure.<br />&bull; This medicine is to be given to a child under adult supervision.<br />&bull; Your child should take only one chewable tablet of Broncast Paediatric 4mg once a day as<br />prescribed by your doctor.<br />&bull; It should be taken even when your child has no symptoms or if he/she has an acute asthma attack.<br />For children 2 to 5 years of age:<br />The recommended dose is one 4 mg chewable tablet daily to be taken in the evening.<br />If your child is taking Broncast Paediatric 4mg, be sure that he/she does not take any other<br />medicines that contain the same active ingredient, montelukast.<br />This medicine is for oral use.<br />The tablets are to be chewed before swallowing.<br />Broncast Paediatric 4 mg chewable tablets should not be taken immediately with food; it should be<br />taken at least 1 hour before or 2 hours after food.<br />If your child takes more Broncast Paediatric 4mg than he/she should<br />Contact your child&rsquo;s doctor immediately for advice.<br />There were no side effects reported in the majority of overdose reports. The most frequently<br />occurring symptoms reported with overdose in adults and children included abdominal pain,<br />sleepiness, thirst, headache, vomiting, and hyperactivity.<br />If you forget to give Broncast Paediatric 4mg to your child<br />Try to give Broncast Paediatric 4mg as prescribed. However, if your child misses a dose, just resume the usual schedule of one chewable tablet once daily.<br />Do not give a double dose to make up for a forgotten dose.</p><p>If your child stops taking Broncast Paediatric 4mg<br />Broncast Paediatric 4mg can treat your child&rsquo;s asthma only if he/she continues taking it.<br />It is important for your child to continue taking Broncast Paediatric 4mg for as long as your doctor<br />prescribes. It will help control your child&rsquo;s asthma.<br />If you have any further questions on the use of this medicine, ask your child&rsquo;s doctor or pharmacist.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>4. Possible side effects<br />Like all medicines, this medicine can cause side effects, although not everybody gets them.<br />In clinical studies with montelukast Paediatric 4 mg chewable tablets, the most commonly reported<br />side effects (may affect up to 1 in 10 people) thought to be related to montelukast Paediatric were:<br />&bull; abdominal pain<br />&bull; thirst<br />Additionally, the following side effect was reported in clinical studies with montelukast 10 mg filmcoated<br />tablets and 5 mg chewable tablets:<br />&bull; headache<br />These were usually mild and occurred at a greater frequency in patients treated with montelukast<br />than placebo (a pill containing no medication).<br />Serious side effects<br />Talk with your doctor immediately if you notice any of the following side effects, which may be<br />serious, and for which you may need urgent medical treatment.<br />Uncommon: the following may affect up to 1 in 100 people<br />&bull; allergic reactions including swelling of the face, lips, tongue, and/or throat which may cause<br />difficulty in breathing or swallowing<br />&bull; behaviour and mood related changes: agitation including aggressive behaviour or hostility,<br />depression<br />&bull; seizure<br />Rare: the following may affect up to 1 in 1,000 people<br />&bull; increased bleeding tendency<br />&bull; tremor<br />&bull; palpitations<br />Very rare: the following may affect up to 1 in 10,000 people<br />&bull; combination of symptoms such as flu-like illness, pins and needles or numbness of arms and legs,<br />worsening of pulmonary symptoms and/or rash (Churg-Strauss syndrome) (see section 2)<br />&bull; low blood platelet count<br />&bull; behaviour and mood related changes: hallucinations, disorientation, suicidal thoughts and actions<br />&bull; swelling (inflammation) of the lungs<br />&bull; severe skin reactions (erythema multiforme) that may occur without warning<br />&bull; inflammation of the liver (hepatitis)<br />Other side effects while the medicine has been on the market<br />Very common: the following may affect more than 1 in 10 people<br />&bull; upper respiratory infection<br />Common: the following may affect up to 1 in 10 people<br />&bull; diarrhoea, nausea, vomiting<br />&bull; rash<br />&bull; fever<br />&bull; elevated liver enzymes<br />Uncommon: the following may affect up to 1 in 100 people</p><p>&bull; behaviour and mood related changes: dream abnormalities, including nightmares, trouble sleeping,<br />sleepwalking, irritability, feeling anxious, restlessness<br />&bull; dizziness, drowsiness, pins and needles/numbness<br />&bull; nosebleed<br />&bull; dry mouth, indigestion<br />&bull; bruising, itching, hives<br />&bull; joint or muscle pain, muscle cramps<br />&bull; bedwetting in children<br />&bull; weakness/tiredness, feeling unwell, swelling<br />Rare: the following may affect up to 1 in 1,000 people<br />&bull; behaviour and mood related changes: disturbance in attention, memory impairment, uncontrolled<br />muscle movements<br />Very rare: the following may affect up to 1 in 10,000 people<br />&bull; tender red lumps under the skin, most commonly on your shins (erythema nodosum)<br />&bull; behaviour and mood related changes: obsessive-compulsive symptoms, stuttering.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; Keep this medicine out of the sight and reach of children.<br />&bull; Store below 30&deg;C.<br />&bull; Do not use this medicine after the expiry date which is stated on the label and carton. The expiry<br />date refers to the last day of that month.<br />&bull; Store in the original package in order to protect from light and moisture.<br />&bull; Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to<br />throw away medicines if you no longer use. These measures will help to protect the environment.<br />&bull; Shelf-life: 24 months.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is montelukast. Each chewable tablet contains montelukast sodium which<br />corresponds to 4mg of montelukast.<br />The other ingredients are:<br />&bull; Mannitol<br />&bull; Microcrystalline cellulose<br />&bull; Hydroxypropyl cellulose<br />&bull; Croscarmellose sodium<br />&bull; Red iron oxide<br />&bull; Bubble gum flavor<br />&bull; Aspartame<br />&bull; Colloidal anhydrous silica<br />&bull; Magnesium stearate</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Pink to reddish, round, biconvex, uncoated tablet Debossed with “C1” on one side and plain on the
other side.
Pack size: 28 tablets
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Middle East Pharmaceutical Industries Co Ltd (Avalon Pharma)<br />P.O.Box 4180 Riyadh 11491, Kingdom of Saudi Arabia<br />2nd Industrial City, Riyadh,<br />Tel: +966 (11) 2653948 -2653427<br />Fax: +966 (11) 2654723</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                01/2020
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>ما هو برونكاست 4 ملجم للأطفال؟<br />أقراص برونكاست للأطفال عبارة عن مضادات لمستقبلات اللوكوترين، وتعمل على منع نشاط مواد تسمى اللوكوترايينات.<br />كيف يعمل برونكاست 4 ملجم للأطفال؟<br />يسبب اللوكوترايينات ضيقًا وتورمًا بمجرى التنفس في الرئتين. يخفف برونكاست 4 ملجم للأطفال من أعراض الربو عن طريق منع نشاط<br />اللوكوترايينات، ويساعد في السيطرة على الربو.<br />متى يجب استخدام برونكاست 4 ملجم للأطفال؟<br />لقد وصف الطبيب أقراص برونكاست 4 ملجم للأطفال لعلاج طفلك من مرض الربو، ولمنع ظهور أعراض الربو خلال فترة النهار والليل.<br />5 سنوات، والذين لا يستجيبون بصورة كافية - &bull; يُستخدم برونكاست 4 ملجم للأطفال لعلاج الأطفال المرضى الذين تتراوح أعمارهم بين سن 2<br />لأدوية الربو ويحتاجون إلى تناول علاج إضافي.<br />5 - &bull; تُستخدم أقراص برونكاست 4 ملجم للأطفال أيضًا كعلاج بديل للكورتيكوستيرويدات المستنشقة للمرضى الذين تتراوح أعمارهم بين سن 2<br />سنوات، والذين لم يتناولوا حديثاً الكورتيكوستيرويدات الذي يؤخذ عن طريق الفم لعلاج نوبات الربو وأظهروا أنهم غير قادرين على تناول<br />الكورتيكوستيرويدات المستنشقة.<br />&bull; تساعد أقراص برونكاست 4 ملجم للأطفال أيضًا في منع تضييق مجاري التنفس التي تتهيج بأداء التمارين الرياضية للمرضى من عمر عامين فأكبر.<br />سوف يحدد الطبيب المعالج طريقة استخدام أقراص برونكاست 4 ملجم للأطفال، اعتمادًا على الأعراض وشدة مرض الربو لدى طفلك.<br />ما هو مرض الربو؟<br />الربو هو حالة مرضية مزَمنة تصيب الإنسان.<br />تتضمن أعراض الربو ما يلي:<br />&bull; صعوبة في التنفس بسبب ضيق مجاري التنفس. ويزداد هذا الضيق سوءًا أو يتحسن نتيجة لحالات مختلفة.<br />&bull; مجرى التنفس الحساس يتأثر بالعديد من المؤثرات، مثل: دخان السجائر، أو حبوب اللقاح، أو برودة الجو، أو التمارين الرياضية.<br />&bull; تورم )التهاب( بطانة مجرى التنفس.<br />وتشمل أعراض الربو أيضًا ما يلي: السعال، والصفير عند التنفس، وضيق الصدر.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>2. ما يجب معرفته قبل تناول طفلك لبرونكاست 4 ملجم للأطفال<br />أخبر طبيبك المعالج إذا كان طفلك يعاني من مشاكل طبية، أو يعاني حالياً من حساسية أو كان يعاني منها سابقًا.<br />لا تعطِ طفلك أقراص برونكاست 4 ملجم للأطفال:<br />&bull; إذا كانت لديه حساسية لمادة مونتيليوكاست أو أي من المكونات الأخرى لهذا الدواء )مدرجة بالقسم السادس(.<br />التحذيرات والاحتياطات<br />تحدث إلى طبيبك المعالج أو الصيدلي قبل إعطاء طفلك أقراص برونكاست 4 ملجم للأطفال:<br />&bull; إذا تدهورت حالة الربو لدى طفلك أو أصبح يتنفس بصعوبة، فأخبر طبيبك على الفور.<br />&bull; إن العلاج بأقراص برونكاست 4 ملجم للأطفال عن طريق الفم لا يعني أن يكون علاجًا لنوبات الربو الحادة. عند حدوث هذه النوبة، يجب اتباع<br />تعليمات الطبيب المعالج التي ذكرها لعلاج لطفلك. ويجب أن تحتفظ لطفلك دائمًا بدواء الإنقاذ السريع للربو الذي يُستخدم عن طريق الاستنشاق؛<br />لاستخدامه في هذه الحالة.<br />&bull; من الضروري أن يتناول طفلك جميع أدوية الربو التي وصفها الطبيب المعالج. ويجب عدم استخدام أقراص برونكاست 4 ملجم للأطفال عوضًا عن<br />أدوية الربو الأخرى التي وصفها الطبيب المعالج لطفلك.<br />&bull; إذا كان طفلك يتناول أدوية لعلاج الربو، يجب عليك استشارة الطبيب المعالج إذا تطورت لديه/لديها مجموعة من الأعراض، مثل: أعراض تشبه<br />أعراض الأنفلونزا، الشعور بوخز أو خدر في الذراعين أو الساقين، وتفاقم في أعراض الأمراض الرئوية و/أو طفح.<br />&bull; يجب ألا يتناول طفلك حمض الأسيتايل ساليسيليك )الأسبرين(، أو الأدوية الأخرى المضادة للالتهاب )التي تعرف أيضًا بمضادات الالتهاب غير<br />إذا أدت إلى تدهور حالة الربو لديه. ))NSAIDs( الستيرويدية أو<br />يجب أن يكون المرضى على دراية بحالات الإصابة بالاضطرابات النفسية والعصبية )مثل: التغيرات السلوكية والتغيرات المتعلقة بالحالة المزاجية(<br />التي تم تسجيلها بين البالغين والمراهقين والأطفال ممن يتناولون أقراص برونكاست )راجع القسم الرابع(. إذا كان طفلك يعاني من أي من هذه<br />الأعراض خلال فترة تناوله لأقراص برونكاست، يجب استشارة الطبيب المعالج.<br />الاستخدام للأطفال والمراهقين<br />لا تقم بإعطاء هذا الدواء للأطفال دون العامين.<br />تتوافر أشكال صيدلانية مختلفة لهذا الدواء للمرضى من الأطفال دون سن 18 عامًا حسب الفئة العمرية للطفل.<br />الأدوية الأخرى ودواء برونكاست 4 ملجم للأطفال<br />أخبر طبيبك المعالج أو الصيدلي إذا كان طفلك يتناول أو تناول حديثًا أو سيتناول أي أدوية أخرى، بما في ذلك الأدوية التي تم الحصول عليها دون<br />وصفة طبية.<br />من الممكن أن تؤثر بعض الأدوية في طريقة عمل برونكاست 4 ملجم للأطفال، أو يؤثر برونكاست 4 ملجم للأطفال في طريقة عمل الأدوية الأخرى<br />لدى طفلك.<br />أخبر طبيبك المعالج إذا كان طفلك يتناول الأدوية التالية قبل البدء في تناول أقراص برونكاست 4 ملجم للأطفال:<br />&bull; فينوباربيتال )لعلاج الصرع(<br />&bull; فينيتوين )لعلاج الصرع(<br />&bull; ريفامبيسين )لعلاج السل وبعض أنواع العدوى الأخرى(<br />تناول برونكاست 4 ملجم للأطفال مع الطعام والشراب<br />لا يجب تناول أقراص برونكاست 4 ملجم للأطفال القابلة للمضغ مباشرة مع الطعام، بل يجب تناولها قبل ساعة على الأقل من تناول الطعام، أو بعد<br />ساعتين من تناول الطعام.<br />الحمل والرضاعة:<br />5 سنوات. - لا ينطبق هذا القسم الفرعي على أقراص برونكاست 4 ملجم للأطفال القابلة للمضغ؛ لأنها مخصصة للأطفال الذين تتراوح أعمارهم بين 2<br />قيادة المركبات وتشغيل الآلات<br />5 سنوات. - لا ينطبق هذا القسم الفرعي على أقراص برونكاست 4 ملجم للأطفال القابلة للمضغ؛ لأنها مخصصة للأطفال الذين تتراوح أعمارهم بين 2<br />ومع ذلك، تتعلق المعلومات التالية بالمكون الفعال لهذا الدواء؛ مونتيليوكاست.<br />من غير المتوقع أن تؤثر أقراص برونكاست 4 ملجم للأطفال في قدرتك على قيادة المركبات وتشغيل الآلات. وعلى كل حال، فإن الاستجابة للدواء<br />تختلف من شخص لآخر. وقد تم تسجيل بعض الآثار الجانبية )مثل الدوار والدوخة( مع أقراص برونكاست 4 ملجم للأطفال، والتي قد تؤثر في قدرة<br />المريض على قيادة المركبات أو تشغيل الآلات.<br />تحتوي أقراص برونكاست 4 ملجم للأطفال القابلة للمضغ على الأسبارتام، وهو مصدر للفينيل ألانين والصوديوم<br />اضطراب نادر ووراثي في العملية الأيضية(، يجب أن تأخذ في ( &rdquo;phenylketonuria&rdquo; إذا كان طفلك يعاني من مرض الفينايل آيتون يوريا<br />الاعتبار أن كل قرص من أقراص برونكاست 4 ملجم للأطفال القابلة للمضغ يحتوي على 0.08 ملجم من الأسبارتام أيْ ما يعادل 0.0449 ملجم<br />من الفينيل ألانين.<br />يحتوي هذا الدواء على أقل من 1 مليمول ) 23 ملجم( لكل قرص، أيْ أنه &quot;خالٍ من الصوديوم&quot; بشكل أساسي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>3. كيفية تناول برونكاست 4 ملجم للأطفال<br />اعطِ لطفلك دائمًا هذا الدواء حسب وصف الطبيب المعالج أو الصيدلي. وعليك استشارة الطبيب المعالج لطفلك أو الصيدلي في حالة لم تكن متأكدًا.<br />&bull; يُعطى هذا الدواء للأطفال تحت إشراف البالغين.<br />&bull; يجب أن يتناول طفلك قرصًا واحدًا من أقراص برونكاست 4 ملجم للأطفال القابلة للمضغ مرة واحدة يوميًّا حسب وصف الطبيب المعالج.<br />&bull; يجب تناوله حتى إن لم تظهر أعراض على طفلك، أو في حال كان يعاني من نوبة ربو حادة.<br />5 سنوات: - للأطفال بين عمر 2<br />الجرعة الموصى بها هي قرص واحد من أقراص برونكاست 4 ملجم للأطفال القابلة للمضغ يوميًّا في المساء.<br />إذا كان طفلك يتناول أقراص برونكاست 4 ملجم للأطفال، يجب التأكد من عدم تناوله لدواء آخر يحتوي على المادة الفعالة نفسها؛ مونتيليوكاست.<br />يجب تناول هذا الدواء عن طريق الفم.<br />يجب مضغ هذه الأقراص قبل بلعها.<br />لا يجب تناول أقراص برونكاست 4 ملجم للأطفال القابلة للمضغ مباشرة مع الطعام، بل يجب تناولها قبل ساعة على الأقل من تناول الطعام، أو بعد<br />ساعتين من تناول الطعام.<br />إذا تناول طفلك أقراص برونكاست 4 ملجم للأطفال أكثر مما يجب<br />استشر الطبيب المعالج لطفلك على الفور.<br />لم تسجل أي آثار جانبية في معظم التقارير التي تتحدث عن تجاوز الجرعة. أكثر الأعراض الجانبية شيوعًا التي تم تسجيل حدوثها عند تجاوز الجرعة<br />لدى البالغين والأطفال تضمنت: ألم البطن، والنعاس، والعطش، والصداع، والتقيؤ، وفرط الحركة.</p><p>حاول إعطاء طفلك أقراص برونكاست 4 ملجم للأطفال كما هو موصوف. وعلى كل حال، إذا نسيت إعطاء الجرعة لطفلك، فتابع الجدول المعتاد<br />للجرعة؛ وهو قرص واحد قابل للمضغ مرة واحدة يوميًّا.<br />لا تعطِ طفلك جرعة إضافية لتعويض الجرعة المنسية.<br />إذا توقف طفلك عن تناول أقراص برونكاست 4 ملجم للأطفال<br />يمكن أن تعالج أقراص برونكاست 4 ملجم للأطفال مرض الربو لدى طفلك فقط إذا داوم على تناوله.<br />من المهم أن يستمر طفلك في تناول أقراص برونكاست 4 ملجم للأطفال طوال الفترة التي وصفها الطبيب المعالج له. سيساعد ذلك في السيطرة على&nbsp;مرض الربو لديه.</p><p>إذا كانت لديك أسئلة إضافية حول استخدام هذا الدواء، فاسأل طبيبك المعالج لطفلك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جميع الأدوية، يمكن لهذا الدواء أن يتسبب في حدوث آثار جانبية، على الرغم من أنها لا تصيب الجميع.<br />وفي الدراسات الإكلينيكية المتعلقة بأقراص مونتيليوكاست 4 ملجم للأطفال القابلة للمضغ، وُجد أن غالبية الآثار الجانبية شيوعًا المسجلة )تؤثر على ما<br />يصل إلى 1 من كل 10 أشخاص( والتي تتعلق بالعلاج بمونتيليوكاست للأطفال هي:<br />&bull; آلام البطن<br />&bull; العطش<br />بالإضافة إلى ذلك، تم تسجيل الآثار الجانبية التالية في الدراسات الإكلينيكية المتعلقة بأقراص مونتيليوكاست 10 ملجم المغلفة والأقراص القابلة للمضغ<br />5 ملجم.<br />&bull; الصداع<br />اذا كان هذا العارض بدرجة خفيفة وحدث بغالبية كبرى للمرضى الذين تم إعطاؤهم مونتيليوكاست مقارنةً بالعلاج الوهمي )القرص الذي لا يحتوي<br />على دواء(.<br />آثار جانبية خطيرة<br />تحدث مع طبيبك المعالج على الفور إذا لاحظت أيًّا من الآثار الجانبية التالية، التي قد تكون خطيرة، وقد تحتاج إلى علاج طبي على الفور.<br />غير شائعة: قد تؤثر الآثار التالية على ما يصل إلى 1 من كل 100 شخص:<br />&bull; تفاعلات حساسية تشمل تورم الوجه، والشفتين، واللسان و/أو الحلق؛ مما قد يؤدي لصعوبة في التنفس أو البلع<br />&bull; تغيرات في السلوك والمزاج: التهيج، بما في ذلك السلوك الفظ أو العداونية أو الاكتئاب<br />&bull; نوبة قلبية<br />نادرة: قد تؤثر الآثار التالية على ما يصل إلى 1 من كل 1000 شخص:<br />&bull; زيادة قابلية النزيف<br />&bull; الرعاش<br />&bull; الخفقان<br />نادرة جدًّا: قد تؤثر الآثار التالية على ما يصل إلى 1 من كل 10000 شخص:<br />&bull; مزيج من الأعراض مثل: مرض يشبه الأنفلونزا، ووخزات وتنميل أو خدر في الذراعين والساقين، وتدهور أعراض الأمراض الرئوية و/أو طفح<br />)متلازمة تشيرج-ستراوس( )راجع القسم الثاني(<br />&bull; انخفاض عدد الصفائح الدموية<br />&bull; تغيرات في السلوك والمزاج: الهلوسة، التشوش، الأفكار والأفعال الانتحارية<br />&bull; تورم )التهاب( الرئتين<br />&bull; تفاعلات جلدية شديدة )حمامي متعدد الأشكال(، قد تحدث دون سابق إنذار<br />&bull; التهاب الكبد<br />الآثار الجانبية الأخرى خلال بيع الدواء في الأسواق<br />شائعة جدًّا: قد تؤثر الآثار التالية على أكثر من 1 من كل 10 شخص:<br />&bull; عدوى الجهاز التنفسي العلوي<br />شائعة: قد تؤثر الآثار التالية على ما يصل إلى 1 من كل 10 أشخاص:<br />&bull; الإسهال، الغثيان، التقيؤ<br />&bull; طفح جلدي<br />&bull; حمى<br />&bull; ارتفاع مستوى إنزيمات الكبد</p><p>&nbsp;</p><p>غير شائعة: قد تؤثر الآثار التالية على ما يصل إلى 1 من كل 100 شخص:<br />&bull; تغيرات في السلوك والمزاج: اضطراب الأحلام، بما في ذلك رؤية كوابيس، صعوبة في النوم، المشي في أثناء النوم، التهيج، الشعور بالقلق، الأرق<br />&bull; دوخة، نعاس، وخز، إبر/خدر<br />&bull; نزيف الأنف<br />&bull; جفاف الفم، عسر الهضم<br />&bull; كدمات، حكة، شرى<br />&bull; آلام في المفاصل أو العضلات، تشنجات العضلات<br />&bull; التبول اللاإرادي عند الأطفال<br />&bull; الضعف/التعب، الشعور بالإعياء، تورم<br />نادرة: قد تؤثر الآثار التالية على ما يصل إلى 1 من كل 1000 شخص:<br />&bull; تغيرات في السلوك والمزاج: اضطراب نقص الانتباه، ضعف الذاكرة، حركات العضلات اللاإرادية<br />نادرة جدا: قد تؤثر الآثار التالية على ما يصل إلى 1 من كل 10000 شخص:<br />&bull; تكتلات حمراء رقيقة تحت الجلد، غالبًا ما تكون على الساق )حمامي عقدية(<br />&bull; تغيرات في السلوك والمزاج: أعراض الوسواس القهري، التلعثم</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&bull; يُحفظ هذا الدواء بعيدًا عن مرأى ومتناول الأطفال.<br />&bull; يُحفظ في درجة حرارة أقل من 30 درجة مئوية.<br />&bull; لا تتناول هذا الدواء بعد تاريخ الانتهاء الموضح على الملصق والعلبة. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.<br />&bull; يُحفظ في العبوة الأصلية لتحميه من الضوء والرطوبة.<br />&bull; ينبغي عدم التخلُّص من الأدوية في مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي الخاص بك عن كيفية التخلُّص من الأدوية التي لم تعد<br />لازمة. ستساعد هذه التدابير في حماية البيئة.<br />&bull; فترة الصلاحية: 24 شهرًا.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المادة الفعالة هي مونتيليوكاست. يحتوي كل قرص قابل للمضغ على مونتيليوكاست صوديوم يعادل مونتيليوكاست 4 ملجم.<br />المحتويات الأخرى للقرص هي:<br />&bull; مانيتول<br />&bull; السليلوز دقيق التبلور<br />&bull; هيدروكسي بروبيل السليلوز<br />&bull; كروس كارميلوز الصوديوم<br />&bull; أكسيد الحديد الأحمر<br />&bull; نكهة من العلكة الفقاعية<br />&bull; أسبرتام<br />&bull; السيليكا اللامائية الغروانية<br />&bull; ستيرات المغنسيوم</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>ما هو شكل أقراص برونكاست 4 ملجم للأطفال؟ وماهي محتويات العبوة؟<br />والجهة الأخرى لا يوجد عليها شيء. &quot;C أقراص ذات لون وردي تميل إلى الحمرة، دائرية الشكل، غير مغلفة ثنائية التحدب، محفور على جهة &quot; 1<br />العبوة تحتوي على 28 قرصًا مغلفاً.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>شركة الشرق الأوسط للصناعات الدوائية المحدودة</p><p>(أفالون فارما)</p><p>ص.ب. 4180 الرياض 11491</p><p>المدينة الصناعية الثانية، الرياض، المملكة العربية السعودية</p><p>هاتف</p><p>0966112653948 &ndash; 00966112653427</p><p>فاكس</p><p>00966112654723</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            01/2020
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Broncast Paediatric 4 mg chewable tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                One chewable tablet contains montelukast sodium, which is equivalent to 4 mg montelukast.
Excipients with known effect: This medicine contains 0.08 mg aspartame per tablet which is equivalent to 0.0449 mg
of Phenylalanine.
This medicine contains less than 1mmol (23 mg) sodium per tablet, that is to say essentially 'sodium-free'.
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Chewable tablet.
Pink to reddish, round, biconvex, uncoated tablet Debossed with “C1” on one side and plain on the other side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>with mild to moderate persistent asthma who are inadequately controlled on inhaled corticosteroids and in whom &ldquo;asneeded&rdquo;<br />short-acting &beta;-agonists provide inadequate clinical control of asthma.<br />Broncast Paediatric 4 mg may also be an alternative treatment option to low-dose inhaled corticosteroids for 2 to 5<br />years old patients with mild persistent asthma who do not have a recent history of serious asthma attacks that required<br />oral corticosteroid use, and who have demonstrated that they are not capable of using inhaled corticosteroids (see<br />section 4.2).<br />Broncast Paediatric 4 mg is also indicated in the prophylaxis of asthma from 2 years of age and older in which the<br />predominant component is exercise-induced bronchoconstriction.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology<br />This medicinal product is to be given to a child under adult supervision. The recommended dose for paediatric patients<br />2-5 years of age is one 4 mg chewable tablet daily to be taken in the evening. If taken in connection with food, Broncast<br />Paediatric 4 mg should be taken 1 hour before or 2 hours after food. No dosage adjustment within this age group is<br />necessary.<br />General recommendations<br />The therapeutic effect of Broncast Paediatric 4 mg on parameters of asthma control occurs within one day. Patients<br />should be advised to continue taking Broncast Paediatric 4 mg even if their asthma is under control, as well as during<br />periods of worsening asthma.<br />No dosage adjustment is necessary for patients with renal insufficiency, or mild to moderate hepatic impairment. There<br />are no data on patients with severe hepatic impairment. The dosage is the same for both male and female patients.</p><p>Broncast Paediatric 4 mg as an alternative treatment option to low-dose inhaled corticosteroids for mild, persistent<br />asthma<br />Montelukast is not recommended as monotherapy in patients with moderate persistent asthma. The use of montelukast<br />as an alternative treatment option to low-dose inhaled corticosteroids for children with mild persistent asthma should<br />only be considered for patients who do not have a recent history of serious asthma attacks that required oral<br />corticosteroid use and who have demonstrated that they are not capable of using inhaled corticosteroids (see section<br />4.1). Mild persistent asthma is defined as asthma symptoms more than once a week but less than once a day, nocturnal<br />symptoms more than twice a month but less than once a week, normal lung function between episodes. If satisfactory<br />control of asthma is not achieved at follow-up (usually within one month), the need for an additional or different antiinflammatory<br />therapy based on the step system for asthma therapy should be evaluated. Patients should be periodically<br />evaluated for their asthma control.<br />Broncast Paediatric 4 mg as prophylaxis of asthma for 2 to 5 years old patients in whom the predominant component<br />is exercise-induced bronchoconstriction<br />In 2 to 5 years old patients, exercise-induced bronchoconstriction may be the predominant manifestation of persistent<br />asthma that requires treatment with inhaled corticosteroids. Patients should be evaluated after 2 to 4 weeks of treatment<br />with montelukast. If satisfactory response is not achieved, an additional or different therapy should be considered.<br />Therapy with Broncast Paediatric 4 mg in relation to other treatments for asthma<br />When treatment with Broncast Paediatric 4 mg is used as add-on therapy to inhaled corticosteroids, Broncast Paediatric<br />4 mg should not be abruptly substituted for inhaled corticosteroids (see section 4.4).<br />10 mg film-coated tablets are available for adults and adolescents 15 years of age and older.</p><p>Paediatric population<br />Do not give Broncast Paediatric 4 mg chewable tablets to children less than 2 years of age. The safety and efficacy of<br />Broncast Paediatric 4 mg chewable tablets in children less than 2 years of age has not been established.<br />5 mg chewable tablets are available for paediatric patients 6 to 14 years of age.<br />Method of administration<br />Oral use.<br />The tablets are to be chewed before swallowing.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Patients should be advised never to use oral montelukast to treat acute asthma attacks and to keep their usual<br />appropriate rescue medication for this purpose readily available. If an acute attack occurs, a short-acting inhaled &beta;-<br />agonist should be used. Patients should seek their doctors&#39; advice as soon as possible if they need more inhalations of<br />short-acting &beta;-agonists than usual.<br />Montelukast should not be abruptly substituted for inhaled or oral corticosteroids.<br />There are no data demonstrating that oral corticosteroids can be reduced when montelukast is given concomitantly.<br />In rare cases, patients on therapy with anti-asthma agents including montelukast may present with systemic<br />eosinophilia, sometimes presenting with clinical features of vasculitis consistent with Churg-Strauss syndrome, a<br />condition which is often treated with systemic corticosteroid therapy. These cases have been sometimes associated&nbsp;with the reduction or withdrawal of oral corticosteroid therapy. Although a causal relationship with leukotriene receptor<br />antagonism has not been established, physicians should be alert to eosinophilia, vasculitic rash, worsening pulmonary<br />symptoms, cardiac complications, and/or neuropathy presenting in their patients. Patients who develop these symptoms<br />should be reassessed and their treatment regimens evaluated.<br />Treatment with montelukast does not alter the need for patients with aspirin-sensitive asthma to avoid taking aspirin<br />and other non-steroidal anti-inflammatory drugs.<br />Broncast Paediatric 4 mg contains aspartame, a source of phenylalanine. Patients with phenylketonuria should take<br />into account that each 4 mg chewable tablet contains phenylalanine in an amount equivalent to 0.0449 mg<br />phenylalanine per dose.<br />Neuropsychiatric events have been reported in adults, adolescents, and children taking Broncast Paediatric 4 mg (see<br />section 4.8). Patients and physicians should be alert for neuropsychiatric events. Patients and/or caregivers should be<br />instructed to notify their physician if these changes occur. Prescribers should carefully evaluate the risks and benefits<br />of continuing treatment with Broncast Paediatric 4 mg if such events occur.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Montelukast may be administered with other therapies routinely used in the prophylaxis and chronic treatment of<br />asthma. In drug-interactions studies, the recommended clinical dose of montelukast did not have clinically important<br />effects on the pharmacokinetics of the following medicinal products: theophylline, prednisone, prednisolone, oral<br />contraceptives (ethinyl oestradiol/norethindrone 35/1), terfenadine, digoxin and warfarin.<br />The area under the plasma concentration curve (AUC) for montelukast was decreased approximately 40% in subjects<br />with co-administration of phenobarbital. Since montelukast is metabolised by CYP 3A4, 2C8, and 2C9, caution should<br />be exercised, particularly in children, when montelukast is co-administered with inducers of CYP 3A4, 2C8, and 2C9,<br />such as phenytoin, phenobarbital and rifampicin.<br />In vitro studies have shown that montelukast is a potent inhibitor of CYP 2C8. However, data from a clinical drug-drug<br />interaction study involving montelukast and rosiglitazone (a probe substrate representative of medicinal products<br />primarily metabolised by CYP 2C8) demonstrated that montelukast does not inhibit CYP 2C8 in vivo. Therefore,<br />montelukast is not anticipated to markedly alter the metabolism of medicinal products metabolised by this enzyme (e.g.,<br />paclitaxel, rosiglitazone, and repaglinide).<br />In vitro studies have shown that montelukast is a substrate of CYP 2C8, and to a less significant extent, of 2C9, and<br />3A4. In a clinical drug-drug interaction study involving montelukast and gemfibrozil (an inhibitor of both CYP 2C8 and<br />2C9) gemfibrozil increased the systemic exposure of montelukast by 4.4-fold. No routine dosage adjustment of<br />montelukast is required upon co-administration with gemfibrozil or other potent inhibitors of CYP 2C8, but the physician<br />should be aware of the potential for an increase in adverse reactions.<br />Based on in vitro data, clinically important drug interactions with less potent inhibitors of CYP 2C8 (e.g., trimethoprim)<br />are not anticipated. Co-administration of montelukast with itraconazole, a strong inhibitor of CYP 3A4, resulted in no<br />significant increase in the systemic exposure of montelukast.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<br />Animal studies do not indicate harmful effects with respect to effects on pregnancy or embryonal/foetal development.<br />Limited data from available pregnancy databases do not suggest a causal relationship between Broncast Paediatric 4<br />mg and malformations (i.e. limb defects) that have been rarely reported in worldwide post-marketing experience.<br />Broncast Paediatric 4 mg may be used during pregnancy only if it is considered to be clearly essential.</p><p>Breast-feeding<br />Studies in rats have shown that montelukast is excreted in milk (see section 5.3). It is unknown whether<br />montelukast/metabolites are excreted in human milk.<br />Broncast Paediatric 4 mg may be used in breast-feeding mothers only if it is considered to be clearly essential.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Broncast Paediatric 4 mg has no or negligible influence on the ability to drive and use machines. However, individuals<br />have reported drowsiness or dizziness.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Montelukast has been evaluated in clinical studies in patients with persistent asthma as follows:<br />&bull; 10 mg film-coated tablets in approximately 4,000 adult and adolescent patients 15 years of age and older<br />&bull; 5 mg chewable tablets in approximately 1,750 paediatric patients 6 to 14 years of age, and<br />&bull; 4 mg chewable tablets in 851 paediatric patients 2 to 5 years of age.<br />Montelukast has been evaluated in a clinical study in patients with intermittent asthma as follows:<br />&bull; 4 mg granules and chewable tablets in 1,038 paediatric patients 6 months to 5 years of age.</p><p>With prolonged treatment in clinical trials with a limited number of patients for up to 2 years for adults, and up to 12<br />months for paediatric patients 6 to 14 years of age, the safety profile did not change.<br />Cumulatively, 502 paediatric patients 2 to 5 years of age were treated with montelukast for at least 3 months, 338 for 6<br />months or longer, and 534 patients for 12 months or longer. With prolonged treatment, the safety profile did not change<br />in these patients either.<br />Tabulated list of Adverse Reactions<br />Adverse reactions reported in post-marketing use are listed, by System Organ Class and specific Adverse Reactions,<br />in the table below. Frequency Categories were estimated based on relevant clinical trials.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In chronic asthma studies, montelukast has been administered at doses up to 200 mg/day to adult patients for 22 weeks<br />and in short-term studies, up to 900 mg/day to patients for approximately one week without clinically important adverse<br />experiences.<br />There have been reports of acute overdose in post-marketing experience and clinical studies with montelukast. These<br />include reports in adults and children with a dose as high as 1,000 mg (approximately 61 mg/kg in 42 months old child).<br />The clinical and laboratory findings observed were consistent with the safety profile in adults and paediatric patients.<br />There were no adverse experiences in the majority of overdose reports.<br />Symptoms of overdose<br />The most frequently occurring adverse experiences were consistent with the safety profile of montelukast and included<br />abdominal pain, somnolence, thirst, headache, vomiting, and psychomotor hyperactivity.<br />Management of overdose<br />No specific information is available on the treatment of overdose with montelukast. It is not known whether montelukast<br />is dialysable by peritoneal- or haemo-dialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Leukotriene receptor antagonist.<br />Mechanism of action<br />The cysteinyl leukotrienes (LTC4, LTD4, LTE4) are potent inflammatory eicosanoids released from various cells including<br />mast cells and eosinophils. These important pro-asthmatic mediators bind to cysteinyl leukotriene receptors (CysLT)<br />found in the human airway and cause airway actions, including bronchoconstriction, mucous secretion, vascular<br />permeability, and eosinophil recruitment.<br />Pharmacodynamic effects<br />Montelukast is an orally active compound which binds with high affinity and selectivity to the CysLT1 receptor. In clinical<br />studies, montelukast inhibits bronchoconstriction due to inhaled LTD4 at doses as low as 5 mg. Bronchodilation was<br />observed within 2 hours of oral administration. The bronchodilation effect caused by a &beta;-agonist was additive to that<br />caused by montelukast. Treatment with montelukast inhibited both early- and late-phase bronchoconstriction due to<br />antigen challenge. Montelukast, compared with placebo, decreased peripheral blood eosinophils in adult and paediatric<br />patients. In a separate study, treatment with montelukast significantly decreased eosinophils in the airways (as<br />measured in sputum). In adult and paediatric patients 2 to 14 years of age, montelukast, compared with placebo,<br />decreased peripheral blood eosinophils while improving clinical asthma control.<br />Clinical efficacy and safety<br />In studies in adults, montelukast, 10 mg once daily, compared with placebo, demonstrated significant improvements in<br />morning FEV1 (10.4% vs 2.7% change from baseline), AM peak expiratory flow rate (PEFR) (24.5 L/min vs 3.3 L/min<br />change from baseline), and significant decrease in total &beta;-agonist use (-26.1% vs -4.6% change from baseline).<br />Improvement in patient-reported daytime and night-time asthma symptoms scores was significantly better than placebo.<br />Studies in adults demonstrated the ability of montelukast to add to the clinical effect of inhaled corticosteroid (% change<br />from baseline for inhaled beclomethasone plus montelukast vs beclomethasone, respectively for FEV1: 5.43% vs 1.04%;<br />&beta;-agonist use: -8.70% vs 2.64%). Compared with inhaled beclomethasone (200 &mu;g twice daily with a spacer device),<br />montelukast demonstrated a more rapid initial response, although over the 12-week study, beclomethasone provided<br />a greater average treatment effect (% change from baseline for montelukast vs beclomethasone, respectively for<br />FEV1: 7.49% vs 13.3%; &beta;-agonist use: -28.28% vs -43.89%). However, compared with beclomethasone, a high<br />percentage of patients treated with montelukast achieved similar clinical responses (e.g., 50% of patients treated with<br />beclomethasone achieved an improvement in FEV1 of approximately 11% or more over baseline while approximately<br />42% of patients treated with montelukast achieved the same response).</p><p>In a 12-week, placebo-controlled study in paediatric patients 2 to 5 years of age, montelukast 4 mg once daily improved<br />parameters of asthma control compared with placebo irrespective of concomitant controller therapy (inhaled/nebulised<br />corticosteroids or inhaled/nebulised sodium cromoglycate). Sixty percent of patients were not on any other controller<br />therapy. Montelukast improved daytime symptoms (including coughing, wheezing, trouble breathing and activity<br />limitation) and night-time symptoms compared with placebo. Montelukast also decreased &ldquo;as needed&rdquo; &beta;-agonist use<br />and corticosteroid rescue for worsening asthma compared with placebo. Patients receiving montelukast had more days<br />without asthma than those receiving placebo. A treatment effect was achieved after the first dose.<br />In a 12-month, placebo-controlled study in paediatric patients 2 to 5 years of age with mild asthma and episodic<br />exacerbations, montelukast 4 mg once daily significantly (p&le;0.001) reduced the yearly rate of asthma exacerbation<br />episodes (EE) compared with placebo (1.60 EE vs. 2.34 EE, respectively), [EE defined as &ge;3 consecutive days with<br />daytime symptoms requiring &beta;-agonist use, or corticosteroids (oral or inhaled), or hospitalisation for asthma]. The<br />percentage reduction in yearly EE rate was 31.9%, with a 95% CI of 16.9, 44.1.<br />In a placebo-controlled study in paediatric patients 6 months to 5 years of age who had intermittent asthma but did not<br />have persistent asthma, treatment with montelukast was administered over a 12-month period, either as a once-daily<br />4 mg regimen or as a series of 12-day courses that each were started when an episode of intermittent symptoms began.</p><p>No significant difference was observed between patients treated with montelukast 4 mg or placebo in the number of<br />asthma episodes culminating in an asthma attack, defined as an asthma episode requiring utilization of health-care<br />resources such as an unscheduled visit to a doctor&#39;s office, emergency room, or hospital; or treatment with oral,<br />intravenous, or intramuscular corticosteroid.<br />In an 8-week study in paediatric patients 6 to 14 years of age, montelukast 5 mg once daily, compared with placebo,<br />significantly improved respiratory function (FEV1 8.71% vs 4.16% change from baseline; AM PEFR 27.9 L/min vs 17.8<br />L/min change from baseline) and decreased &ldquo;as-needed&rdquo; &beta;-agonist use (-11.7% vs +8.2% change from baseline).<br />In a 12-month study comparing the efficacy of montelukast to inhaled fluticasone on asthma control in paediatric patients<br />6 to 14 years of age with mild persistent asthma, montelukast was non-inferior to fluticasone in increasing the<br />percentage of asthma rescue-free days (RFDs), the primary endpoint. Averaged over the 12-month treatment period,<br />the percentage of asthma RFDs increased from 61.6 to 84.0 in the montelukast group and from 60.9 to 86.7 in the<br />fluticasone group. The between group difference in LS mean increase in the percentage of asthma RFDs was<br />statistically significant (-2.8 with a 95% CI of -4.7, -0.9), but within the limit pre-defined to be clinically not inferior. Both<br />montelukast and fluticasone also improved asthma control on secondary variables assessed over the 12 months<br />treatment period:<br />FEV1 increased from 1.83 L to 2.09 L in the montelukast group and from 1.85 L to 2.14 L in the fluticasone group. The<br />between-group difference in LS mean increase in FEV1 was -0.02 L with a 95% CI of -0.06, 0.02. The mean increase<br />from baseline in % predicted FEV1 was 0.6% in the montelukast treatment group, and 2.7% in the fluticasone treatment<br />group. The difference in LS means for the change from baseline in the % predicted FEV1 was significant: -2.2% with a<br />95% CI of -3.6, -0.7.<br />The percentage of days with &beta;-agonist use decreased from 38.0 to 15.4 in the montelukast group, and from 38.5 to<br />12.8 in the fluticasone group. The between group difference in LS means for the percentage of days with &beta;-agonist use<br />was significant: 2.7 with a 95% CI of 0.9, 4.5.<br />The percentage of patients with an asthma attack (an asthma attack being defined as a period of worsening asthma<br />that required treatment with oral steroids, an unscheduled visit to the doctor&#39;s office, an emergency room visit, or<br />hospitalisation) was 32.2 in the montelukast group and 25.6 in the fluticasone group; the odds ratio (95% CI) being<br />significant: equal to 1.38 (1.04, 1.84).<br />The percentage of patients with systemic (mainly oral) corticosteroid use during the study period was 17.8% in the<br />montelukast group and 10.5% in the fluticasone group. The between group difference in LS means was significant:<br />7.3% with a 95% CI of 2.9; 11.7.<br />Significant reduction of exercise-induced bronchoconstriction (EIB) was demonstrated in a 12-week study in adults<br />(maximal fall in FEV1 22.33% for montelukast vs 32.40% for placebo; time to recovery to within 5% of baseline<br />FEV1 44.22 min vs 60.64 min). This effect was consistent throughout the 12-week study period. Reduction in EIB was<br />also demonstrated in a short-term study in paediatric patients 6 to 14 years of age (maximal fall in FEV1 18.27% vs<br />26.11%; time to recovery to within 5% of baseline FEV1 17.76 min vs 27.98 min). The effect in both studies was demonstrated at the end of the once-daily dosing interval.<br />In aspirin-sensitive asthmatic patients receiving concomitant inhaled and/or oral corticosteroids, treatment with<br />montelukast, compared with placebo, resulted in significant improvement in asthma control (FEV1 8.55% vs -1.74%<br />change from baseline and decrease in total &beta;-agonist use -27.78% vs 2.09% change from baseline).</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption<br />Montelukast is rapidly absorbed following oral administration. For the 10 mg film-coated tablet, the mean peak plasma<br />concentration (Cmax) is achieved 3 hours (Tmax) after administration in adults in the fasted state. The mean oral<br />bioavailability is 64%. The oral bioavailability and Cmax are not influenced by a standard meal. Safety and efficacy were<br />demonstrated in clinical trials where the 10 mg film-coated tablet was administered without regard to the timing of food ingestion.</p><p>For the 5 mg chewable tablet, the Cmax is achieved in 2 hours after administration in adults in the fasted state. The mean<br />oral bioavailability is 73% and is decreased to 63% by a standard meal.<br />After administration of the 4 mg chewable tablet to paediatric patients 2 to 5 years of age in the fasted state, Cmax is<br />achieved 2 hours after administration. The mean Cmax is 66% higher while mean Cmin is lower than in adults receiving a&nbsp;10 mg tablet.</p><p>Distribution<br />Montelukast is more than 99% bound to plasma proteins. The steady-state volume of distribution of montelukast<br />averages 8-11 litres. Studies in rats with radiolabelled montelukast indicate minimal distribution across the blood-brain<br />barrier. In addition, concentrations of radiolabelled material at 24 hours post-dose were minimal in all other tissues.<br />Biotransformation<br />Montelukast is extensively metabolised. In studies with therapeutic doses, plasma concentrations of metabolites of<br />montelukast are undetectable at steady state in adults and children.<br />Cytochrome P450 2C8 is the major enzyme in the metabolism of montelukast. Additionally, CYP 3A4 and 2C9 may<br />have a minor contribution, although itraconazole, an inhibitor of CYP 3A4, was shown not to change pharmacokinetic<br />variables of montelukast in healthy subjects that received 10 mg montelukast daily. Based on in vitro results in human<br />liver microsomes, therapeutic plasma concentrations of montelukast do not inhibit cytochromes P450 3A4, 2C9, 1A2,<br />2A6, 2C19, or 2D6. The contribution of metabolites to the therapeutic effect of montelukast is minimal.<br />Elimination<br />The plasma clearance of montelukast averages 45 ml/min in healthy adults. Following an oral dose of radiolabelled<br />montelukast, 86% of the radioactivity was recovered in 5-day faecal collections and &lt;0.2% was recovered in urine.<br />Coupled with estimates of montelukast oral bioavailability, this indicates that montelukast and its metabolites are<br />excreted almost exclusively via the bile.<br />Characteristics in Patients<br />No dosage adjustment is necessary for the elderly or mild to moderate hepatic insufficiency. Studies in patients with<br />renal impairment have not been undertaken. Because montelukast and its metabolites are eliminated by the biliary<br />route, no dose adjustment is anticipated to be necessary in patients with renal impairment. There are no data on thepharmacokinetics of montelukast in patients with severe hepatic insufficiency (Child-Pugh score &gt;9).<br />With high doses of montelukast (20- and 60-fold the recommended adult dose), a decrease in plasma theophylline<br />concentration was observed. This effect was not seen at the recommended dose of 10 mg once daily.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In animal toxicity studies, minor serum biochemical alterations in ALT, glucose, phosphorus and triglycerides were<br />observed which were transient in nature. The signs of toxicity in animals were increased excretion of saliva, gastrointestinal<br />symptoms, loose stools and ion imbalance. These occurred at dosages which provided &gt;17-fold the systemic<br />exposure seen at the clinical dosage. In monkeys, the adverse effects appeared at doses from 150 mg/kg/day (&gt;232-<br />fold the systemic exposure seen at the clinical dose). In animal studies, montelukast did not affect fertility or reproductive<br />performance at systemic exposure exceeding the clinical systemic exposure by greater than 24-fold. A slight decreasein pup body weight was noted in the female fertility study in rats at 200 mg/kg/day (&gt;69-fold the clinical systemic exposure). In studies in rabbits, a higher incidence of incomplete ossification, compared with concurrent control animals,<br />was seen at systemic exposure &gt;24-fold the clinical systemic exposure seen at the clinical dose. No abnormalities were seen in rats. Montelukast has been shown to cross the placental barrier and is excreted in breast milk of animals.<br />No deaths occurred following a single oral administration of montelukast sodium at doses up to 5,000 mg/kg in mice and rats (15,000 mg/m2 and 30,000 mg/m2 in mice and rats, respectively), the maximum dose tested. This dose is equivalent to 25,000 times the recommended daily adult human dose (based on an adult patient weight of 50 kg).</p><p>Montelukast was determined not to be phototoxic in mice for UVA, UVB or visible light spectra at doses up to 500<br />mg/kg/day (approximately &gt;200-fold based on systemic exposure).<br />Montelukast was neither mutagenic in in vitro and in vivo tests nor tumorigenic in rodent species.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>‐ Mannitol<br />‐ Microcrystalline cellulose<br />‐ Hydroxypropyl cellulose<br />‐ Croscarmellose sodium<br />‐ Red iron oxide<br />‐ Bubble gum flavor<br />‐ Aspartame<br />‐ Colloidal anhydrous silica<br />‐ Magnesium stearate</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.<br />Store in the original package in order to protect from light and moisture.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Packaged in Aluminum/Aluminum blister pack.<br />Pack of 28 tablets.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Middle East Pharmaceutical Industries Co. Ltd (Avalon-Pharma)
2nd industrial City, P.O.Box 4180 Riyadh 11491, Kingdom of Saudi Arabia
Tel: 920010564, Fax: +966 (11) 2654723
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                01/2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>